Follow
Jorge Gómez Miragaya
Jorge Gómez Miragaya
University of Basel, Department of Biomedicine
Verified email at unibas.ch
Title
Cited by
Cited by
Year
Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population
J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ...
Stem cell reports 8 (5), 1392-1407, 2017
772017
RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation
G Yoldi, P Pellegrini, EM Trinidad, A Cordero, J Gomez-Miragaya, ...
Cancer research 76 (19), 5857-5869, 2016
612016
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs
A Blancafort, A Giró-Perafita, G Oliveras, S Palomeras, C Turrado, ...
PLoS One 10 (6), e0131241, 2015
612015
Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer
L Piqué, A Martinez de Paz, D Piñeyro, A Martínez-Cardús, ...
Oncogene 38 (45), 7106-7112, 2019
542019
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
F Mateo, EJ Arenas, H Aguilar, J Serra-Musach, GR De Garibay, J Boni, ...
Oncogene 36 (19), 2737-2749, 2017
412017
The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models
J Gómez-Miragaya, S Moran, ME Calleja-Cervantes, A Collado-Sole, ...
Molecular Cancer Research 17 (10), 2063-2076, 2019
222019
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
J Gomez-Miragaya, A Diaz-Navarro, R Tonda, S Beltran, L Palomero, ...
Cancer research 79 (16), 4258-4270, 2019
202019
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
J Gomez-Miragaya, E González-Suárez
Molecular & Cellular Oncology 4 (4), e1338208, 2017
152017
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
A Sanz-Moreno, S Palomeras, K Pedersen, B Morancho, T Pascual, ...
Breast Cancer Research 23, 1-18, 2021
132021
Nicotinamide N‐methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer
JP Couto, M Vulin, C Jehanno, MM Coissieux, B Hamelin, A Schmidt, ...
The EMBO journal 42 (13), e112559, 2023
52023
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
M Ciscar, EM Trinidad, G Perez‐Chacon, M Alsaleem, M Jimenez, ...
EMBO Molecular Medicine 15 (4), e16715, 2023
12023
RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts
M Ciscar, EM Trinidad, H Perez-Montoyo, M Alsaleem, ...
bioRxiv, 2021.12. 13.470911, 2021
12021
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
S Palomeras, K Pedersen, B Morancho, T Pascual, J Gomez-Miragaya, ...
Breast Cancer Research 23 (1), 2021
2021
Identification of mechanisms of acquired resistance to taxanes in triple negative breast cancer using patient-derived xenografts: a step closer to clinics
J Gómez Miragaya
Universitat de Barcelona, 2018
2018
Therapeutic opportunities of RANK pathway in breast cancer
H Perez Montoyo, J Gomez Miragaya, EM Trinidad, A Martinez-Aranda, ...
Cancer Research 76 (14_Supplement), 4389-4389, 2016
2016
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
A Giro-Perafita, G Oliveras Serrat, S Palomeras, C Turrado, ...
PLoS One, 2015, vol. 10, num. 6, p. e0131241, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–16